Atox Bio clos­es $30M round as it speeds through late-stage tri­als

Is­rael’s Atox Bio has raised $30 mil­lion — the lat­est in a long line of eq­ui­ty deals — to help push its im­mune mod­u­la­tors through late-stage clin­i­cal tri­als.

The com­pa­ny is work­ing on im­mune mod­u­la­tors for pa­tients with se­vere in­fec­tions and tis­sue in­jury. The com­pa­ny’s lead drug, called Rel­tec­i­mod, is a pep­tide that mod­u­lates the body’s im­mune re­sponse, boost­ing the pa­tient’s abil­i­ty to fight in­fec­tion while re­duc­ing the like­li­hood of tis­sue dam­age to key or­gans dur­ing in­flam­ma­to­ry re­spons­es to se­vere in­fec­tions or in­juries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.